Why are so many people here interested in Biotech?

I genuinely don’t get it. Do you find the tech exciting? Are you guys from med backgrounds?

I mean, out of all the sectors in public equities, biotech seems: extremely niche, with very few spots; not that popular among investors (I for one have NEVER heard someone investing in the sector); and seems extremely cyclical, so job security is much lower than say TMT or Financials.

This is not to shit on anyone who likes/wants biotech, this is a genuine question. really.


Based on the discussions and Q&A sessions on Wall Street Oasis, the interest in biotech among finance professionals can be attributed to several factors:

  1. Innovation and Impact: Biotech is at the forefront of scientific innovation, working on breakthroughs that can significantly impact healthcare and quality of life. This includes developing new drugs, medical devices, and treatments that can cure diseases or improve patient outcomes.

  2. Intellectual Challenge: The biotech sector is known for its complexity, involving a deep understanding of scientific processes, clinical trials, and regulatory environments. This intellectual challenge attracts professionals who are eager to engage in continuous learning and problem-solving.

  3. Financial Potential: Despite being perceived as niche and cyclical, biotech offers substantial financial opportunities. The sector is known for its high-risk, high-reward nature, especially in areas like drug development, where successful products can generate significant revenue.

  4. Diverse Opportunities: While it may seem that biotech has fewer spots compared to more traditional sectors, it actually offers a variety of roles across venture capital, equity research, and corporate finance, particularly in companies ranging from startups to established pharmaceutical firms.

  5. Personal Motivation: Many individuals are drawn to biotech due to personal reasons, such as a background in life sciences or personal experiences with medical conditions. These motivations drive a passion for contributing to advancements in healthcare.

While biotech might not be as universally popular as sectors like TMT (Technology, Media, Telecom) or financials, its appeal lies in its potential to drive significant scientific and financial outcomes, making it an exciting field for those interested in a convergence of science and finance.

Sources: Biotech finance: from IB to VC / HF to funded startup, What's the catch in CRE?, Q&A: Pharmaceutical/Biotech Industry, Biotech/Life Sciences Vertical in IB: Day to day, How Do I Get Smart in Biotechnology Space?

I'm an AI bot trained on the most helpful WSO content across 17+ years.

Definitely pays the most. It’s also more interesting than tech. Barrier to entry is high than tech.

Most people on this forum dreamed of being a banker. Most people in biotech are previous scientists so we have less connections in this industry.


As a complete newb (finishing my PhD), what does compensation look like for the first few years at a L/S biotech HF, say 1.5B AUM?


Couple different things about this. I think for one, since it's such a niche vertical, people come here to ask questions since things arent as straight forward as TMT or other sectors. Because of the dynamic of PhDs and MDs sitting in BS/SS associate seats and IB associate seats, the question about pay is fair. It's odd to think about that a fresh college grad in a biotech ER seat is making 75% of what a PhD or MD would make in the same role. 

To me, I find the science interesting. Pharma is a large part of the US healthcare system (obviously), and biotech is an exciting sector because Pharma always looks for opportunities to develop the next great drug through M&A. Not to mention that you are interacting with (potential clients / pitches / DD process) some of the smartest people in the industry who are on the cutting edge of science. 

The mix of science, business, and real life consequences is an intersection that is unique. IB / HF / ER places you somewhere in that intersection.

Most Helpful

Because there is "moat."  Good analysis of biotech companies requires a different skillset than other sectors.  I would argue that I could take a TMT analyst and get him up to speed analyzing A&D, consumer products, etc. in a relatively short time frame.  The only hard skill really required in these sectors is modeling which any kid that's been through 2 years of IB can probably do proficiently enough.

I don't think that I can take a former banking analyst and train them to do good analysis of biotech companies.  It takes a ton of time and resources to develop the clinical diligence skills necessary to do good analysis.  People with advanced life sciences degrees have a leg up in this regard as they've been reading papers/textbooks in an academic setting and have learned how to get through loads of material on a given disease expeditiously.

As such, as compared to other sectors, the pool of qualified candidates for biotech seats is shallower.


No not really.  Covering life science tools, large-cap biopharma, healthcare services (hospitals, nursing homes, etc.) is much the same as covering any other sector.  Medical Devices/Diagnostics might offer some "moat" for those with a scientific backgrounds...but I believe price movements are still largely dictated by quarterly earnings, regulatory decision, etc. rather than clinical data as the pace of innovation in Medical Devices/Diagnostics is much slower than it is in biotech.  


Also would like to add that returns in biotech investing (not pharma) skew alpha (vs. beta) due to the binary outcomes of these companies. Most biotech HF returns are driven by favorable clinical trial readout catalysts vs. broader market trends. Easy to point to your exact contribution/clinical analysis that led to the investment vs. investing in a more beta-driven industry where it can be hard to isolate alpha/your true edge. 

These companies are typically pre-revenue, so things like market access, consumer preference, sales & marketing efficiency simply don't matter. It's pure science. 

Think about a SM fund where it can be extremely challenging and political to (a) isolate alpha from fund performance and (b) allocate that alpha to the various IPs. Biotech investing removes this layer and your comp is much easier to justify. 


My SO trades pharmaceuticals at a pod shop. Would argue it is the best sector for market-neutral L/S investing and is printing cash. The alpha pool (i.e. binary clinical trials as mentioned above) is just very huge and there are lots of trading opportunities. Hard to pick up the sector from scratch without any science background (but not impossible). Try reading the science behind those drugs and you will understand why it has the widest moat.


lol you asked rich toad this too. TMT will never come close to biotech. This isn’t 08 and it’ll never be 08 again. Go get a PhD or MD if you wanna make real money on the SS. TMT is sourced by the summer analyst class. They put out separate posts of biotech analyst and associates. Your biotech counterparts in ER will 110% out earn you. Any monkey can do TMT lololol


Et molestiae eligendi sed praesentium vero repudiandae quam soluta. Tempora sed eligendi mollitia amet repellat. Vel beatae dolor qui illo.

Dolores aut deserunt sed cupiditate modi ut. Nostrum ipsam fugit dolorem facere quibusdam deserunt veritatis facere. Quisquam aut quam aliquid dolorum officiis culpa quis unde. Amet aut illum ea quis corporis ea. Blanditiis culpa et consequatur aut alias est error. Voluptatem cumque nobis tenetur totam quia ullam. Et blanditiis tenetur officia aut eaque provident id veritatis.

Nam tenetur ipsam quia. Pariatur eveniet in aut fugiat possimus ipsum. Omnis adipisci rerum vitae illo et atque esse. Sed repudiandae officia voluptatem est.

Officia mollitia minus dicta quibusdam necessitatibus maxime et enim. Enim adipisci et magnam rerum. Sed pariatur natus alias et enim repellat et.

Career Advancement Opportunities

June 2024 Hedge Fund

  • Point72 98.9%
  • D.E. Shaw 97.9%
  • Citadel Investment Group 96.8%
  • Magnetar Capital 95.8%
  • AQR Capital Management 94.7%

Overall Employee Satisfaction

June 2024 Hedge Fund

  • Magnetar Capital 98.9%
  • D.E. Shaw 97.8%
  • Blackstone Group 96.8%
  • Two Sigma Investments 95.7%
  • Citadel Investment Group 94.6%

Professional Growth Opportunities

June 2024 Hedge Fund

  • AQR Capital Management 99.0%
  • Point72 97.9%
  • D.E. Shaw 96.9%
  • Magnetar Capital 95.8%
  • Citadel Investment Group 94.8%

Total Avg Compensation

June 2024 Hedge Fund

  • Portfolio Manager (9) $1,648
  • Vice President (23) $474
  • Director/MD (12) $423
  • NA (6) $322
  • 3rd+ Year Associate (25) $287
  • Manager (4) $282
  • Engineer/Quant (71) $274
  • 2nd Year Associate (30) $251
  • 1st Year Associate (73) $190
  • Analysts (227) $179
  • Intern/Summer Associate (23) $131
  • Junior Trader (5) $102
  • Intern/Summer Analyst (253) $90
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”


redever's picture
Betsy Massar's picture
Betsy Massar
Secyh62's picture
BankonBanking's picture
GameTheory's picture
dosk17's picture
kanon's picture
CompBanker's picture
DrApeman's picture
Linda Abraham's picture
Linda Abraham
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”